Zacks Small Cap Has Positive Outlook of ABEO FY2025 Earnings

Abeona Therapeutics Inc (NASDAQ:ABEO - Free Report) - Analysts at Zacks Small Cap upped their FY2025 EPS estimates for Abeona Therapeutics in a research report issued on Monday, May 19th. Zacks Small Cap analyst D. Bautz now forecasts that the biopharmaceutical company will earn ($0.64) per share for the year, up from their previous forecast of ($0.74). The consensus estimate for Abeona Therapeutics' current full-year earnings is ($1.16) per share.

Other equities research analysts also recently issued reports about the stock. Oppenheimer initiated coverage on shares of Abeona Therapeutics in a report on Wednesday, March 5th. They issued an "outperform" rating and a $16.00 price target on the stock. Wall Street Zen downgraded shares of Abeona Therapeutics from a "hold" rating to a "sell" rating in a report on Thursday, May 15th. HC Wainwright increased their price target on shares of Abeona Therapeutics from $15.00 to $20.00 and gave the stock a "buy" rating in a report on Wednesday, April 30th. Alliance Global Partners reissued a "buy" rating on shares of Abeona Therapeutics in a report on Thursday, May 15th. Finally, Stifel Nicolaus lowered their price target on shares of Abeona Therapeutics from $21.00 to $20.00 and set a "buy" rating on the stock in a report on Friday, May 16th. One research analyst has rated the stock with a sell rating and five have issued a buy rating to the company's stock. According to MarketBeat, the stock has an average rating of "Moderate Buy" and a consensus price target of $18.50.

Abeona Therapeutics Price Performance

Shares of Abeona Therapeutics stock traded down $0.16 on Thursday, reaching $6.42. The stock had a trading volume of 957,198 shares, compared to its average volume of 619,860. Abeona Therapeutics has a 1 year low of $3.93 and a 1 year high of $7.32. The company has a market cap of $328.43 million, a P/E ratio of -2.39 and a beta of 1.68. The company has a current ratio of 6.12, a quick ratio of 6.12 and a debt-to-equity ratio of 0.31. The business's 50 day moving average is $5.29 and its two-hundred day moving average is $5.56.

Abeona Therapeutics (NASDAQ:ABEO - Get Free Report) last released its quarterly earnings data on Thursday, May 15th. The biopharmaceutical company reported ($0.24) EPS for the quarter, beating the consensus estimate of ($0.35) by $0.11.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently bought and sold shares of the business. Twinbeech Capital LP bought a new position in Abeona Therapeutics during the fourth quarter valued at approximately $58,000. Squarepoint Ops LLC bought a new position in Abeona Therapeutics during the fourth quarter valued at approximately $67,000. Cannon Global Investment Management LLC bought a new position in Abeona Therapeutics during the first quarter valued at approximately $67,000. Oxford Asset Management LLP bought a new position in Abeona Therapeutics during the fourth quarter valued at approximately $118,000. Finally, Balyasny Asset Management L.P. bought a new position in Abeona Therapeutics during the fourth quarter valued at approximately $190,000. 80.56% of the stock is currently owned by institutional investors.

Insider Buying and Selling

In related news, CEO Vishwas Seshadri sold 25,000 shares of the company's stock in a transaction that occurred on Monday, March 31st. The shares were sold at an average price of $4.78, for a total value of $119,500.00. Following the transaction, the chief executive officer now directly owns 1,355,322 shares in the company, valued at approximately $6,478,439.16. This represents a 1.81% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Mark Alvino sold 8,000 shares of the stock in a transaction that occurred on Friday, May 16th. The shares were sold at an average price of $5.68, for a total transaction of $45,440.00. Following the transaction, the director now owns 92,435 shares in the company, valued at $525,030.80. The trade was a 7.97% decrease in their ownership of the stock. The disclosure for this sale can be found here. 6.90% of the stock is owned by company insiders.

Abeona Therapeutics Company Profile

Abeona Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on developing and delivering gene therapy products for severe and life-threatening rare diseases. The company's lead programs are EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB); ABO-102, which are AAV based gene therapies for Sanfilippo syndrome type A; and ABO-101, an adeno-associated virus (AAV) based gene therapies for Sanfilippo syndrome type B.